
    
      The study is designed to examine the efficacy and safety of AD109 to treat obstructive sleep
      apnea. The study is a four-period single-dose randomized crossover design in which patients
      will undergo overnight polysomnographic (PSG) testing with dosing of one of the following 4
      treatments: AD109, atomoxetine, R-oxybutynin or placebo. Participants will return 2 weeks
      after their final crossover PSG for an end of study (EOS) visit.
    
  